Daily non-political popular news in brief.

Natural mechanism for immune suppression paves way for cancer trials

03-28-2007 · EurekAlert!

A natural mechanism pirated by tumors and HIV to evade the immune response is opening the door to better treatment for these conditions, researchers say.

Keywords: natural, mechanism, immune, suppression, paves, way, cancer, trials, pave, trial

« Previous | Next »

Similar news on "Natural mechanism for immune suppression paves way for cancer trials":

Drug-based on MGH discovery may significantly improve treatment of dangerous blood disorder
01-31-2008 · EurekAlert!
Two clinical trials of the novel drug romiplostim show that it significantly improved platelet levels in patients with chronic immune thrombocytopenic purpura, a hematologic disorder that can cause uncontrolled bleeding. An international research team reports Phase 3 trial results for the drug, which duplicates the action of a natural hormone discovered by a Massachusetts General Hospital investigator, in the Feb. 2 issue of The Lancet.
Similar news · Read more »
Drug based on MGH discovery may significantly improve treatment of dangerous blood disorder
01-31-2008 · EurekAlert!
Two clinical trials of the novel drug romiplostim show that it significantly improved platelet levels in patients with chronic immune thrombocytopenic purpura, a hematologic disorder that can cause uncontrolled bleeding. An international research team reports Phase 3 trial results for the drug, which duplicates the action of a natural hormone discovered by a Massachusetts General Hospital investigator, in the Feb. 2 issue of the Lancet.
Similar news · Read more »
From clinical cancer research: rethinking therapeutic cancer vaccine trials
07-03-2007 · EurekAlert!
Ongoing therapeutic cancer vaccine trials have yet to show evidence of vaccines spurring a patient's immune system to shrink tumors -- yet patients who receive these vaccines in trials tend to live longer and respond better to subsequent treatment. In the July 1 issue of Clinical Cancer Research, a journal of the American Association for Cancer Research, a team of National Cancer Institute researchers asks a fundamental question: are we looking at cancer vaccine trials the wrong way?
Similar news · Read more »
Stanford researchers identify immune dysfunction in melanoma patients
05-07-2007 · EurekAlert!
Researchers at Stanford have begun to shed light on why the human immune system isn't able to stop such cancers as melanoma, suggesting answers that could pave the way for better treatment of this often-fatal illness. In a small study, the scientists found that the immune cells in a majority of people with this deadly skin cancer fail to respond properly to a molecule called interferon, which normally activates the immune system.
Similar news · Read more »
JCI table of contents: Nov. 1, 2007
11-01-2007 · EurekAlert!
This release contains summaries, links to PDFs, and contact information for the following newsworthy papers to be published Nov. 1, 2007, in the JCI, including: Mice predict the effectiveness of orally taken drugs; Stressed out skin loses its antimicrobial defense mechanism; The chemical peroxynitrite tolerates pain; OX40L helps trigger anti-cancer immune responses; Macrophages are not all seeing in the eye; I(r)oning out the mechanism of kidney functions; and others.
Similar news · Read more »
Einstein researchers discover how a key dietary vitamin is absorbed
11-30-2006 · EurekAlert!
Researchers at the Albert Einstein College of Medicine of Yeshiva University have found the mechanism by which the B vitamin folate -- a crucially important nutrient -- is absorbed by the intestinal tract. Their findings solve a longstanding mystery as to how folates in the diet are absorbed and pave the way for a genetic test that can save the lives of infants who lack the ability to absorb folate.
Similar news · Read more »
Zanzibar study paves way for mass co-delivery of 3 antiparasitic drugs
01-22-2008 · EurekAlert!
Findings from a new study in Zanzibar, published Jan. 23 in PLoS Neglected Tropical Diseases, pave the way for the World Health Organization to recommend the mass co-delivery of three antiparasitic drugs for the first time. The study shows the safety of delivering three drugs simultaneously -- ivermectin, albendazole and praziquantel -- in order to tackle three diseases, elephantiasis, soil-transmitted worms, and schistosomiasis.
Similar news · Read more »
Taking the wraps off drug safety data from clinical trials
03-06-2007 · EurekAlert!
A new analysis by researchers at the Harvard School of Public Health (HSPH) and Brigham and Women's Hospital (BWH) of laws and regulations governing public disclosure of clinical trial data submitted to the Food and Drug Administration suggests changes should be made to the way the FDA implements its policy regarding the confidentiality of those data.
Similar news · Read more »
A chemotherapy drug packs a one-two punch
02-20-2007 · EurekAlert!
How cancer cells are killed could turn out to be an important element in activating a patient's immune system. A new study shows that one chemotherapy drug may kill tumor cells in such a way that the immune system can recognize the cancerous cells and help fight the disease more effectively.
Similar news · Read more »
Tequila raw ingredient being developed into drug-carrier that targets colon diseases
03-27-2007 · EurekAlert!
Compounds derived from the blue agave, a fruit used to make tequila, show promise as a natural, more effective way to deliver drugs to the colon than conventional drug-carriers, according to chemists at the University of Guadalajara in Mexico. The discovery could lead to improved treatments for a variety of colon diseases, including ulcerative colitis, irritable bowel and cancer, they say. The research will be presented in March at the American Chemical Society national meeting.
Similar news · Read more »